ADC Therapeutics director gets 45,000 RSU grant

ADC Therapeutics SA director Jean-Pierre Bizzari received an annual grant of 45,000 restricted stock units (RSUs) under the company’s 2019 Equity Incentive Plan for board service.

Rhea-AI Filing Summary

ADC Therapeutics SA director Jean-Pierre Bizzari received an annual grant of 45,000 restricted stock units (RSUs) under the company’s 2019 Equity Incentive Plan for board service. The RSUs vest on the earlier of one year from the grant date or the 2027 annual shareholder meeting, and each RSU converts into one common share.

To cover tax withholding on previously vested RSUs, the company withheld 12,600 common shares at $3.08 per share. After these compensation-related transactions, Bizzari directly holds 139,302 common shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider BIZZARI JEAN-PIERRE

Role Director

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Shares	12,600	$3.08	$39K
Grant/Award	Common Shares	45,000	$0.00	$0.00

Holdings After Transaction: Common Shares — 139,302 shares (Direct)

Footnotes (2)

1. F1. Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
2. F2. Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Key Figures

RSU grant size: 45,000 shares Tax withholding shares: 12,600 shares Withholding price: $3.08 per share +2 more

5 metrics

RSU grant size 45,000 shares Annual director RSU grant under 2019 Equity Incentive Plan

Tax withholding shares 12,600 shares Shares withheld to cover tax obligations on prior RSU vesting

Withholding price $3.08 per share Price used for 12,600 withheld common shares

Holdings after transactions 139,302 shares Common shares directly owned after RSU grant and tax withholding

Shares after grant before withholding 151,902 shares Direct holdings following RSU grant, prior to tax-withholding disposition

Key Terms

restricted stock units ("RSUs"), 2019 Equity Incentive Plan, tax withholding obligations, contingent right to receive one share

4 terms

restricted stock units ("RSUs") financial

"Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2019 Equity Incentive Plan financial

"annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director"

tax withholding obligations financial

"Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting"

contingent right to receive one share financial

"Each RSU represents a contingent right to receive one share of the Issuer's common stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did ADC Therapeutics (ADCT) grant to director Jean-Pierre Bizzari?

ADC Therapeutics granted Jean-Pierre Bizzari 45,000 restricted stock units (RSUs) for service as a director. The award was made under the 2019 Equity Incentive Plan, with each RSU representing a contingent right to receive one common share upon vesting.

When do Jean-Pierre Bizzari’s new ADC Therapeutics RSUs vest?

Bizzari’s RSUs vest on the earlier of one year from the grant date or the date of the 2027 Annual Meeting of Shareholders. Vesting is conditioned on his continued service to ADC Therapeutics as a director during this period.

Why were 12,600 ADC Therapeutics shares withheld from Jean-Pierre Bizzari?

ADC Therapeutics withheld 12,600 common shares to satisfy Bizzari’s tax withholding obligations related to the vesting of previously granted restricted share units. This is a non-market, administrative disposition rather than an open-market sale of shares.

What is Jean-Pierre Bizzari’s ADC Therapeutics shareholding after these Form 4 transactions?

Following the RSU grant and tax withholding share disposition, Jean-Pierre Bizzari directly holds 139,302 ADC Therapeutics common shares. This figure reflects his position after the 12,600 shares were withheld to meet tax obligations on earlier RSU vesting.

Were Jean-Pierre Bizzari’s ADC Therapeutics transactions open-market buys or sells?

No, the filing shows a grant of 45,000 RSUs and a tax-withholding disposition of 12,600 shares at $3.08 per share. These are compensation and tax-related entries, not discretionary open-market purchases or sales of ADC Therapeutics stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 05:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BIZZARI JEAN-PIERRE

(Last) (First) (Middle)

430 MOUNTAIN AVENUE, SUITE 404

(Street)

NEW PROVIDENCE NEW JERSEY 07974

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ADC Therapeutics SA [ ADCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/01/2026		A		45,000(1)	A	$0	151,902	D
Common Shares	06/03/2026		F(2)		12,600	D	$3.08	139,302	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

2. Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Remarks:

	/s/ Lisa Kallebo, as Attorney-in-Fact for Jean-Pierre Bizzari	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)